title: Janumet: a combination product suitable for use in patients with Type 2 diabetes.
abstract: Inhibition of the enzyme dipeptidyl peptidase-4 represents the latest pharmacologic intervention to become available to assist patients with Type 2 diabetes to achieve glycemic control. A combination tablet of sitagliptin (Januvia) and metformin HCl (Glucophage) is now available from Merck (Janumet). The FDA has approved this drug for use in patients who are not adequately controlled by taking either sitagliptin or metformin HCl alone or for patients who are at present taking both simultaneously. Sitagliptin has been shown to be safe and effective at 100 mg daily doses. When given in combination with metformin the effect on glycemic control is thought to be complementary and possibly additive.
authors.affiliation: Washington State University, College of Pharmacy, Department of Pharmacotherapy, Pullman, WA, USA. jreynolds@wsu.edu
authors.forename: Jonathan Kent
authors.initials: JK
authors.lastname: Reynolds
authors.forename: Joshua J
authors.initials: JJ
authors.lastname: Neumiller
authors.forename: R Keith
authors.initials: RK
authors.lastname: Campbell
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D004338:Drug Combinations; D004347:Drug Interactions; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D008687:Metformin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D000068899:Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D011719:Pyrazines; D000068899:Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; D014230:Triazoles; D052216:Glucagon-Like Peptide 1; D008687:Metformin; D000068900:Sitagliptin Phosphate